Date: 2015-12-18
Type of information: update on patient enrollment
phase: 2
Announcement: update
Company: AstraZeneca (UK)
Product: durvalumab (MEDI4736)
Action
mechanism:
Disease: locally advanced or metastatic programmed death ligand-1 (PD-L1) positive non-small cell lung cancer (NSCLC) that lacks epidermal growth factor receptor (EGFR) or ALK alterations
Therapeutic area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
Name
Phase
Line of treatment
Population
Design
Timelines
Status
Early disease
Monotherapy
ADJUVANT
III
N/A
Stage Ib-IIIa NSCLC
durvalumab vs placebo
Data expected 2020
Recruiting
PACIFIC
III
N/A
Stage III unresect-able NSCLC
durvalumab vs placebo
Data expected 2017
Recruiting
Advanced/metastatic disease
Monotherapy
ATLANTIC
II
3rd line
PD-L1 pos. NSCLC
durvalumab (single arm)
Full data 2016
-
Combination therapy
ARCTIC
III
3rd line
NSCLC
durvalumab vs SoC (PD-L1 pos.) or durvalumab vs tremelimumab vs durva + treme vs SoC (PD-L1 neg.)
Data expected 2017
Recruiting
MYSTIC
III
1st line
NSCLC (PFS endpoint)
durvalumab vs durva + treme vs SoC
Data expected 2017
First patient dosed
NEPTUNE
III
1st line
NSCLC (OS endpoint)
durva + treme vs SoC
Data expected 2018
Awaiting first patient dosed
-
III
1st line
NSCLC
durvalumab + chemotherapy +/- tremelimumab
In preparation
CAURAL
III
2nd line
T790M+ NSCLC
osimertinib vs osimertinib + durvalumab
Data expected 2018
Initiated enrolment; currently on partial clinical hold to characterise incidence of interstitial lung disease
Name
Phase
Line of treatment
Population
Design
Timelines
Status
Monotherapy
HAWK
II
2nd line
PD-L1 pos. SCCHN
durvalumab (single arm)
Data expected
H2 2016
Recruiting
Indication granted FDA Fast Track designation
Combination therapy
CONDOR
II
2nd line
PD-L1 neg. SCCHN
durvalumab vs tremelimumab vs durva + treme
Data expected 2017
Recruiting
EAGLE
III
2nd line
SCCHN
durvalumab vs durva + treme vs SoC
Data expected 2018
In preparation
KESTREL
III
1st line
SCCHN
durvalumab vs durva + treme vs SoC
Data expected 2018
In preparation
Name
Phase
Line of treatment
Population
Design
Timelines
Status
DANUBE
III
1st line
Cisplatin chemo-therapy-eligible/ineligible
durvalumab vs durva + treme vs SoC
Data expected 2018
First patient dosed
Name
Phase
Line of treatment
Indication
Design
Timelines
Status
-
II
2nd/3rd line
Metastatic gastric cancer
durvalumab vs tremelimumab vs durva + treme
In preparation
-
II
2nd line
Unresect-able liver cancer
durvalumab vs tremelimumab vs durva + treme
In preparation
ALPS
II
2nd line
Unresect-able liver cancer
durva + treme (single arm)
In preparation